PENSACOLA, Fla. and NASHVILLE, Tenn., Jan. 7, 2025 /PRNewswire/ -- ActiGraph, the global leader in wearable digital health technology for clinical research and development, has announced the acquisition of Biofourmis Connect, a division of Biofourmis that delivers an AI-driven, digital trial platform tailored for the life science industry. The combined solution will create a market-leading, unified software and data ecosystem for the modernization of clinical research throughout the drug-product lifecycle and across therapeutic areas.This strategic acquisition enables ActiGraph to deliver the industry's most comprehensive and trusted digital health solution, supporting a wide range of clinical use cases with a device-agnostic platform and patient-centric approach. ActiGraph's leading-edge, medical-grade LEAP wearable technology will be integrated alongside other medical-grade devices, including ECG, pulse oximetry, spirometry, and blood pressure, powered by regulatory-cleared algorithms. ActiGraph is further elevating its leadership in the remote and real-time capture of continuous, high-precision digital health data and will address new areas of high unmet need, such as objective assessments of pain and prediction of Cytokine Release Syndrome (CRS) risk in oncology and immunology trials.Boosted by more than 30 proprietary AI-driven algorithms and practical expertise working with the FDA and EMA, ActiGraph will expand its support of biopharma clients throughout the full life cycle of their assets with bespoke digital biomarker programs

Healthtech unicorn Biofourmis axed about 30 employees from its Singapore and India offices at the end of November, people familiar with the matter told Tech in Asia. However, the exact number of retrenched staff per country remains unclear. The move comes just a month after US-headquartered Biofourmis and General Atlantic-backed CopilotIQ announced a merger to form an AI-driven platform aimed at providing in-home healthcare. Tech in Asia has reached out to Biofourmis for comment.Photo credit: BiofourmisBiofourmis underwent two rounds of layoffs last year. The first occurred before Kuldeep Singh Rajput, the company’s CEO at the time, stepped down in August 2023. The second involved 130 employees and took place months later in October, when the firm began winding down operations in Singapore